Redcare Pharmacy stock: MPCM raises target as outlook holds

Published on 11/10/2026 at 18:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redcare Pharmacy stock faces a split analyst picture after MPCM lifted its target while Jefferies held its view. Management kept its 2026 outlook unchanged.

Analyst targets meet operating progress

MPCM retained its Buy rating while raising its valuation target after Redcare Pharmacy's third-quarter performance.
Revenue, prescription sales and adjusted EBITDA all increased year over year in the third quarter.
Management kept its 2026 growth and margin outlook unchanged, leaving execution as the key test.

Redcare Pharmacy, NL0012044747, Illustration mit AI erstellt.

Redcare Pharmacy stock is caught between a higher MPCM valuation target and an unchanged company outlook. AD HOC NEWS reported on Tuesday, November 10, that MPCM raised its target from 120 euros to 125 euros on November 3 while retaining its Buy rating. The report also highlights the operating figures behind the valuation debate.

Redcare Pharmacy stock traded at 73.30 euros on Lang & Schwarz at 18:07 CET on Tuesday, November 10, 0.48 percent below the Xetra close of Tuesday, November 10, at 73.65 euros.

Analyst targets remain divided

MPCM's higher target contrasts with Jefferies, which kept both its Buy rating and its 97-euro target. The difference leaves investors with a broad valuation range and does not represent a change to Redcare Pharmacy's operating guidance. The target increase lifted MPCM's valuation marker by 4.17 percent.

According to AD HOC NEWS, Redcare's third-quarter revenue rose 18 percent year over year to 847 million euros. Prescription revenue increased 31 percent to 358 million euros, while German prescription revenue gained 56 percent to 197 million euros.

Prescription growth drives execution

Adjusted EBITDA rose 68 percent to 29 million euros, and the margin expanded to 3.4 percent from 2.4 percent in the prior-year quarter. Redcare also reported a second consecutive quarter with positive net income and free cash flow of 15 million euros.

The active customer base reached 15.2 million at the end of September. For 2026, management continues to target total revenue growth of 16 to 18 percent, non-prescription growth of 10 to 12 percent, German prescription revenue of 730 million to 760 million euros and an adjusted EBITDA margin of 2.5 to 3.0 percent.

Prescription demand in Germany, margin expansion and customer retention remain the main execution tests. The higher MPCM target supports the valuation case, but it does not remove the need for operating progress.